Recent clinical trials with PDE-5 inhibitors have also shown enhanced intra-tumor T-cells activity and improved patients' outcome in head and neck squamous cell carcinoma (HNSCC) and metastatic melanoma (65–67). Here, PDE5A is linked to head and neck squamous cell carcinoma.